Nordea has on 30 September received the final Capital Joint Decision. The expected Common Equity Tier 1 ratio requirement by 30 September is 17.3%. The Common Equity Tier 1 requirement of 17.3% includes 85 bp (equivalent to a Common Equity Tier 1 requirement of EUR ~1.2bn and a total Own funds requirement of EUR ~1.5bn) due to the PD inspection performed by the college of supervisors (FSAs) during 2016 as well as the corporate risk weight memo (FI Ref. 15-13020). Nordea takes note of the SFSA combined assessment related to the PD inspection and the corporate risk weight memo (FI Ref. 15-13020) of 85 bp. After a thorough review, Nordea’s assessment differs from the SFSA’s strict conclusion. By 30 June 2016, Nordea had a Common Equity Tier 1 ratio of 16.8% (pro forma 17.2% including synthetic securitisation) and expects to have made further significant progress towards meeting its capital and dividend policy targets at the time of the Q3 results announcement. Final decision on the dividend will be taken by the AGM in 2017. - We have over the last decade generated EUR 31bn in capital and strengthened the CET1 ratio from 5.9% to 17.2%. We have done this with one of the most stable earnings streams in Europe. Our balance sheet is among the strongest of European banks, which is reflected through some of the highest credit ratings from all rating agencies. Adjusting to the new requirements will not affect our business, says Group CEO Casper von Koskull. For further information: Rodney Alfvén, Head of Investor Relations, +46 72 235 05 15 Helga Baagøe, Head of Group External Communications, +46 72 141 18 07 The information provided in this press release/report is such that Nordea is required to disclose pursuant to the Swedish Financial Instruments Trading Act (1991:980), the Swedish Securities Markets Act (2007:528) and/or Regulation (EU) No 596/2014 on market abuse.
Final outcome of the 2016 Capital Joint Decision and
Top 10 Most Recent News Articles
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue ReadingTop 5 Most Recently Viewed Articles
Revolutionizing Knee Treatment with Overture's Latest System
Full Commercial Launch of the OvertureTi Knee Resurfacing System Overture Orthopaedics is making headlines as it proudly announces the full commercial launch of its advanced OvertureTi Knee Resurfacing System. This medical device targets early osteoarthritis and cartilage defects effectively, presenting a breakthrough for patients seeking alternatives to traditional joint...
Continue Reading
Elis SA: Key Insights on Recent Share Buyback Activities
Elis SA's Recent Share Buyback Activities Elis SA has made a mark with its recent trading activities associated with its own shares, particularly highlighting a series of transactions carried out during a specified period. Overview of the Buyback Program As part of its strategic financial planning, Elis has engaged in a buyback program that has garnered attention. The...
Continue Reading
Kevin O'Leary's Essential Advice for Startups on Content Investment
O'Leary: Tools Are Cheap, But Talent Isn't Entrepreneur and "Shark Tank" star Kevin O'Leary emphasizes a critical insight for startups: while the cost of creating digital content has drastically reduced, the true value comes from the talent that produces it. O'Leary shared his thoughts in a recent video, indicating that although the cost of technology has significantly...
Continue Reading
The St. James Reinvents Lacrosse with Spencer Ford at the Helm
The St. James Strengthens Lacrosse Initiatives In an exciting development, The St. James has appointed Spencer Ford as the new Director of Lacrosse, ushering in a transformative approach to lacrosse for both boys and girls. With a vast wealth of experience spanning nearly twenty years, Ford is not only a seasoned professional player but also an accomplished coach and...
Continue Reading
Hudbay Minerals Celebrates Permit Approval for Copper World
Hudbay Minerals Receives Final Permit for Copper World Project Hudbay Minerals Inc. (TSX, NYSE: HBM), a prominent player in the mining industry, has taken a significant step forward by securing the final major permit necessary for its Copper World project in Arizona. This milestone not only enhances the company’s operational capacity but also solidifies its commitment...
Continue Reading